Podcasts by The Readout Loud
All episodes
Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay from 2022-02-17T19:03:56
Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines?
We cover all that and more this week. First, STAT's Nichol...
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic from 2022-02-10T19:24:35
Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion?
We cover all that and more this week on “The Readout LOUD,” STAT’s ...
Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids from 2022-02-03T20:48:01
Does President Biden care about the FDA? What can aerobics instructors teach us about genetics? And when can kids get Covid-19 vaccines?
STAT Washington correspondent Nicholas Florko joins...
Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron from 2022-01-27T18:34:12
Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights?
First, we discuss the FDA's decision to halt the use...
Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project from 2022-01-20T19:51:50
With biotech in the dumps, we talk to Oppenheimer analyst Jared Holz about why the world has soured on the sector and what it means for the future of medicine. Then, STAT’s Matthew Herper joins us ...
Listen
Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news from 2022-01-13T19:45:59
First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what...
Listen
Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict from 2022-01-06T21:14:58
First, emergency room physician Craig Spencer joins us to talk about how the Omicron variant is impacting New York City and what the coming months have in store. Then, we look ahead to the New Year...
Listen
Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review from 2021-12-16T20:39:41
We've come to our last episode of the year, and first, STAT’s Helen Branswell joins us to talk about Omicron, boosters, and the past and future of the Covid-19 pandemic. Then, we'll review the year...
Listen
Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron from 2021-12-09T20:55:48
On this week's episode, we kick off the conversation with an update on what researchers are discovering about the Omicron variant of the coronavirus, including new findings from a study involving t...
Listen
Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron from 2021-12-02T19:32:43
Will the first Covid-19 pill be all that useful? How worrisome is Omicron? And when will it be safe to congregate?
First, STAT's Matthew Herper joins us to talk about a tense debate among...
Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving from 2021-11-18T21:01:39
First, epidemiologist Michael Osterholm of the University of Minnesota joins us to talk about Covid-19 case counts, vaccination rates, and the state of the pandemic as we head into the holidays. Th...
Listen
Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine from 2021-11-11T20:01:33
Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the National Institutes of Health over just who invented a Covid-19 vaccine. Then, STAT's Olivia...
Listen
Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga from 2021-11-04T19:59:09
STAT's Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to step down as CEO of Alnylam Pharmaceuticals after ...
Listen
Episode 184: Vaccines for kids, inside Operation Warp Speed, & a big biotech resignation from 2021-10-28T19:56:30
Can the FDA be too transparent? Who deserves credit for Operation Warp Speed? And when is a CEO worth $3 billion?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podc...
Episode 183: Greg Zuckerman on the vaccine race, plus Biogen's troubled launch from 2021-10-21T18:57:18
Wall Street Journal reporter Gregory Zuckerman joins us to share some behind-the-scenes details from race to develop a Covid-19 vaccine, the subject of his new book. We also discuss the latest news...
Listen
Episode 182: The FDA star search, more booster debates, & the future of mRNA from 2021-10-14T20:14:44
STAT Washington correspondent Nicholas Florko joins us to provide an inside look at the eleventh-hour search for a permanent FDA commissioner. We also discuss the latest twist in the debate over Co...
Listen
Episode 181: Brent Hodge on filming Shkreli, the next NIH director, and a looming FDA deadline from 2021-10-07T19:43:35
First, we discuss the scramble to find new leaders for the NIH and FDA, the latest online dustup involving Ginkgo Bioworks, and the growing promise of antiviral treatments for Covid-19. Then, filmm...
Listen
Episode 180: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest from 2021-09-30T19:52:17
First, we welcome STAT reporter Usha Lee McFarling onto the podcast to discuss her investigation into health equity tourism — how white scholars are colonizing research on health disparities. Then,...
Listen
Episode 179: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest from 2021-09-30T19:52:17
First, we welcome STAT reporter Usha Lee McFarling onto the podcast to discuss her investigation into health equity tourism — how white scholars are colonizing research on health disparities. Then,...
Listen
Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout from 2021-09-23T19:35:58
First, STAT's Helen Branswell joins us to discuss the state of the Covid-19 pandemic as we head into another winter. Then, former FDA Commissioner Scott Gottlieb calls in to discuss his new book on...
Listen
Episode 178: Futuristic prosthetics, a treatment for ALS, & intrigue at the Holmes trial from 2021-09-16T19:41:06
Can prosthetic limbs feel real? Is the FDA softening under pressure? And are Rice Krispies Treats admissible in court?
STAT's Gideon Gil joins us to share the remarkable story of an amputa...
Episode 177: Bijan Salehizadeh on Covid tests, plus Verily's moment of truth from 2021-09-09T19:38:38
First, STAT's Erin Brodwin joins us to talk about Verily, Google's big-idea life sciences company that is now under pressure to produce some actual products. Then, health care investor Bijan Salehi...
Listen
Episode 176: Elizabeth Holmes on trial, FDA in disarray, & the quest for Covid antivirals from 2021-09-02T19:00:55
Former Theranos CEO Elizabeth Holmes is finally headed to trial, and we discuss the case and why it might not be an open-and-shut conviction for prosecutors. Then, STAT Washington correspondent Nic...
Listen
Episode 175: Dorit Reiss on vaccine mandates, plus biotech's messy summer from 2021-08-26T20:16:58
First, law professor Dorit Reiss joins us to discuss what the first FDA approval of a Covid-19 vaccine means for vaccination mandates and how this whole issue relates to jaywalking. Then we discuss...
Listen
Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading from 2021-08-19T18:39:47
First, we discuss a sudden spike of FDA rejections, which has resurfaced a time-honored frustration: You can’t always trust biotech companies to be honest about their conversations with the agency....
Listen
Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms from 2021-08-12T20:10:13
First, STAT Washington correspondent Nicholas Florko joins us to explain President Biden's proposal to lower drug prices, how it might affect the 2022 election, and why there's still no nominee for...
Listen
Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's from 2021-08-05T19:16:02
First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT's Helen Branswell joins us to discuss the...
Listen
Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen from 2021-07-29T18:41:15
First, we discuss the CDC's about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covid-19. Then, STAT's Kate Sheridan joins us to dis...
Listen
Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying from 2021-07-22T19:54:37
First, Céline Gounder of NYU’s Grossman School of Medicine joins us to discuss the issue of breakthrough coronavirus infections and whether the U.S. was too quick to unmask. Then, STAT's Rachel Coh...
Listen
Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist from 2021-07-15T20:31:06
First, we'll talk about the future of the FDA, whose acting commissioner will have to step down in November unless she’s given the permanent job. Next, Washington Post reporter Dan Diamond joins us...
Listen
Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer from 2021-07-08T19:46:15
First, we discuss the latest twists following the FDA's widely condemned decision to approve Aduhelm, Biogen's treatment for Alzheimer's disease. Then, our STAT colleague Helen Branswell joins us t...
Listen
Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga, from 2021-07-01T20:32:07
First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT's reporti...
Listen
Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer from 2021-06-24T19:50:48
First, we sift through the week's news, with a major update from Eli Lilly in Alzheimer's disease and new details on the inner workings of the FDA. Then, STAT's Matthew Herper joins us to discuss h...
Listen
Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade from 2021-06-17T19:46:52
First, we sift through the week's news, with some disappointing Covid-19 vaccine data, a pair of setbacks for biotech, and the Wall Street debut of 23andMe. Then, vaccinologist Paul Offit joins us ...
Listen
Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug from 2021-06-10T20:33:37
We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's ...
Listen
Episode 163: Marilynn Marchione on covering the CRISPR babies scandal from 2021-06-03T19:51:23
First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko joins us for a dive into...
Listen
Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA from 2021-05-27T20:41:47
STAT's Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families dealing with the rare disease spinal muscular at...
Listen
Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity from 2021-05-20T20:58:57
First, we discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes. Then, STAT’s Helen Branswell joins us to discuss ...
Listen
Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit from 2021-05-13T20:17:32
Can we prevent the next Covid-19? Has the CDC become too cautious? And how many sensors should be worn to bed? First, our colleague Helen Branswell joins us to discuss where the world went wrong wi...
Listen
Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging from 2021-05-06T21:34:51
First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of cash portends for both companies. Next, Thomas ...
Listen
Episode 157: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt from 2021-04-29T22:45:59
First, STAT Washington correspondent Rachel Cohrs joins us to explain why President Biden's endorsement for drug pricing reform rang hollow to many advocates. Next, virologist Angela Rasmussen call...
Listen
Episode 158: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt from 2021-04-29T20:45:59
First, STAT Washington correspondent Rachel Cohrs joins us to explain why President Biden's endorsement for drug pricing reform rang hollow to many advocates. Next, virologist Angela Rasmussen call...
Listen
Episode 156: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside from 2021-04-22T21:59:46
First, Northwestern University epidemiologist Mercedes Carnethon joins us to weigh on the nation's latest Covid-19 debate: Is it OK to go maskless outdoors? Then, STAT Washington correspondent Nich...
Listen
Episode 157: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside from 2021-04-22T19:59:46
First, Northwestern University epidemiologist Mercedes Carnethon joins us to weigh on the nation's latest Covid-19 debate: Is it OK to go maskless outdoors? Then, STAT Washington correspondent Nich...
Listen
Episode 166: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19 from 2021-04-15T21:46:47
How do you describe a one-in-a-million risk? What's heparin-induced thrombocytopenia? And why's it so hard to find drugs for Covid-19?
We cover all that and more this week on “The Readout ...
Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19 from 2021-04-15T19:46:47
How do you describe a one-in-a-million risk? What's heparin-induced thrombocytopenia? And why's it so hard to find drugs for Covid-19?
We cover all that and more this week on “The Readout ...
Episode 155: AstraZeneca's vaccine woes, compassionate use, & giving out Covid vaccines from 2021-04-08T19:51:02
What's next for AstraZeneca? Are there any right answers when it comes to compassionate use? And how does it feel to give someone a Covid-19 vaccine?
We cover all that and more this week o...
Episode 154: Eleanor Fox on Illumina’s FTC headache, plus Talkspace’s experiment from 2021-04-01T20:54:38
First, STAT’s Mario Aguilar joins us to discuss a fascinating experiment in Nevada, where one city is giving its residents free access to a therapy app — and getting a mixed reception. Then, New Yo...
Listen
Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week from 2021-03-25T20:06:04
We're devoting this week's episode to the week of whiplash news about AstraZeneca's Covid-19 vaccine, subject of a baffling international incident with consequences still unfolding. First, we expla...
Listen
Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea from 2021-03-18T19:53:29
First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain...
Listen
Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer from 2021-03-11T20:31:58
We're joined by Natasha Loder, the health policy editor at The Economist — and a London resident — to get her home-country perspective on the U.K.'s Covid vaccine development efforts. Next, we'll t...
Listen
Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase from 2021-03-04T22:37:24
We discuss Merck's decision to help Johnson & Johnson manufacture vaccine doses and whether it'll be a turning point for the drug industry or a relic of Covid-19 history. Then, as we near the one-y...
Listen
Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise from 2021-02-25T21:45:23
First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children. Then, Wall Street Journal reporter Greg Zucker...
Listen
Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future from 2021-02-18T21:58:40
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay S...
Listen
Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks from 2021-02-11T21:28:40
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech?
We discuss all that and more this week on “The...
Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring from 2021-02-04T21:27:46
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck...
Listen
Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation from 2021-01-28T21:54:14
First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the...
Listen
Episode 144: Remembering STAT's Sharon Begley from 2021-01-22T01:10:14
We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss ...
Listen
Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy from 2021-01-14T21:34:30
We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising d...
Listen
Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview from 2021-01-07T22:08:39
On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk abo...
Listen
Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021 from 2020-12-18T16:56:35
It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.
Listen
Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution from 2020-12-11T19:42:44
Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?
Listen
Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021 from 2020-12-03T21:34:27
Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?
Listen
Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered from 2020-11-19T21:54:31
How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?
Listen
Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary from 2020-11-12T22:34:40
How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?
Listen
Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old from 2020-11-05T22:51
How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20?
We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotec...
Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5 from 2020-10-29T21:22:07
When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?
Listen
Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's from 2020-10-22T20:31:21
Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?
Listen
Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials from 2020-10-15T21:56:14
Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?
Listen
Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos from 2020-10-08T21:03:56
Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?
Listen
Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting from 2020-10-01T20:31:34
Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?
Listen
Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest from 2020-09-24T20:38:57
Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?
Listen
Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round from 2020-09-17T19:34:43
How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild public trust? And when is a steak worth $21 billion?
Listen
Episode 128: AstraZeneca’s Covid-19 vaccine, coronavirus politics, & STAT’s Health Tech Summit from 2020-09-10T20:33:50
Is AstraZeneca’s Covid-19 vaccine in jeopardy? Why can’t politicians and scientists in Washington get along? Did you miss STAT’s first-ever Health Tech Summit?
Listen
Episode 127: Eric Topol on Stephen Hahn, plus Covid-19 vaccine timelines, & the 2000th First Opinion from 2020-09-03T19:22:41
Should the FDA commissioner resign? How fast can vaccine trials move? And what do Chelsea Clinton and Chuck Grassley have in common?
Listen
Episode 126: The FDA's chaotic week, Trump's effect on science, and Musk's big reveal from 2020-08-27T20:52:20
Can the Food and Drug Administration survive Trump? Are drug reviewers in the deep state? And what can Elon Musk teach us about the nature of reality?
Listen
Episode 125: Shocking FDA rejections, a longevity science setback & Derek Lowe on Covid-19 vaccines from 2020-08-20T20:54:35
Did the FDA suddenly get stringent about new drugs? Is longevity research over-hyped? And what can recovered patients teach us about Covid-19 vaccines?
Listen
Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies from 2020-08-13T20:01:03
Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?
Listen
Episode 123: Steven Salzberg's Twitter debate, a health tech mega-deal & Covid-19 vaccine prices from 2020-08-06T20:07:39
Does the future of health tech look like Facebook? Can we cut corners with Covid-19 vaccines? And are journalists slowing down Operation Warp Speed?
Listen
Episode 122: Gary Washburn on the NBA bubble, plus a DIY coronavirus vaccine, & behind VC numbers from 2020-07-30T18:51:38
How much should a Covid-19 vaccine cost? What can basketball teach us about pandemic safety? And just how lucrative is venture capital?
Listen
Episode 121: Kate Bingham on vaccine data, Meg Tirrell on covering Covid-19, & a DNA detective story from 2020-07-23T20:46:01
How soon will we get a Covid-19 vaccine? Why is biotech moving airline stocks? And what can we learn from 1860s science?
Listen
Episode 120: Moderna's vaccine data, saving the U.S. pandemic response & systemic racism in medicine from 2020-07-16T20:17:58
What do we want from a coronavirus vaccine? Can the U.S.’s Covid-19 response be saved? And how can the field of medicine address structural racism?
Listen
Episode 119: Trump's FDA pressure, a microcosm of the pandemic, and squabbling over a vaccine from 2020-07-09T19:19:02
Who will stand up to the White House? How can hospitals protect workers from Covid-19? And what ever happened with Biogen?
Listen
Episode 118: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life from 2020-07-02T17:23:36
What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?
Listen
Episode 117: Covid-19’s U.S. surge, GSK’s mystery whistleblower, and cancer care under coronavirus from 2020-06-25T20:52:59
Is this a second wave or a rising tide? Who’s the real GlaxoSmithKline whistleblower? And what happens to cancer care in a pandemic?
Listen
Episode 116: Ezekiel Emanuel on vaccine politics & Tshaka Cunningham on diversifying genetic testing from 2020-06-18T21:28:10
Can a vaccine be an October surprise? Are journal publishers running a racket? And why is genetics so white?
Listen
Episode 115: The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19 from 2020-06-11T20:46:11
Can a virtual conference feel real? Do scientists have a say in their benefactors' business? And what does it take to get remdesivir in the U.S.?
Listen
Episode 114: The killing of George Floyd, the drug industry's response, and what comes next from 2020-06-04T21:03:21
The killing of George Floyd at the hands of a white Minneapolis police officer has brutally underlined the systemic racism that informs policing, housing, education, and health care in the U.S. Thi...
Listen
Episode 113: Life after a coronavirus vaccine, virtual ASCO, and remembering Larry Kramer from 2020-05-28T19:47:32
What happens after we get a coronavirus vaccine? Can virtual medical meetings replace the real thing? And wasn’t Amazon supposed to disrupt health care?
Listen
Episode 112: Moderna's scant coronavirus data and the plight of the day trader from 2020-05-21T20:10:03
When is a press release worth $5 billion? Can biotech stocks replace sports? And how will we know if a coronavirus vaccine actually works?
Listen
Episode 111: Covid-19 in the White House, a Parkinson’s experiment & public health lessons from porn from 2020-05-14T20:02:11
What can the adult film industry teach us about fighting coronavirus? Does the FDA approve Zoom backgrounds? And is it ethical to fund a study of yourself?
Listen
Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York from 2020-05-07T20:18:43
What if the curve just stays flat? How much should a Covid-19 drug cost? And what's it like on the ground in the epicenter of the novel coronavirus?
Listen
Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day from 2020-04-30T21:25:33
Just how well does Gilead Sciences' Covid-19 drug work? Is politics getting in the way of public health? And who gets the eventual coronavirus vaccine first?
Listen
Episode 108: A vaccine official is ousted, how to use ventilators, & the fate of the JPM conference from 2020-04-23T20:51:04
Why was the infectious disease community in denial about the unfolding pandemic? When can we expect a vaccine? And are ventilators being overused?
Listen
Episode 107: Covid-19 disrupts D.C., how not to be boring on Zoom, and the trial of Elizabeth Holmes from 2020-04-16T19:04:50
What's the proper distance to stand from Sen. Mitch McConnell? How many PowerPoint charts is too many? And when will Theranos get its day in court?
Listen
Episode 106: Privacy in a pandemic, biopharma's big opportunity, and Shkreli's plea for a break from 2020-04-09T20:54:09
Can the drug industry win over Americans? Will the pandemic put an end to privacy? And could Martin Shkreli save the world?
Listen
Episode 105: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA from 2020-04-02T20:06:01
When will things go back to normal? What if a pandemic strikes when you're already sick? And what does Ken Burns know about genomics?
Listen
Episode 104: Fauci's star turn, the latest on coronavirus, and an under-the-radar Alzheimer's drug from 2020-03-26T19:13:28
When can we stop distancing? Does the "deep state" meet over Zoom? And could the amyloid hypothesis come through at last?
Listen
Episode 103: Trump's coronavirus pivot, life inside the ICU & drug development in a pandemic from 2020-03-19T21:05:22
Why did the U.S. change its tune on coronavirus? What's it like to be an ICU nurse right now? And when are we getting a vaccine?
Listen
Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas from 2020-03-12T21:45:10
How long will this pandemic persist? Are U.S. hospitals going to be overwhelmed? And what’s it like to be quarantined on a cruise ship?
Listen
Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China from 2020-03-05T22:28:23
Does “The Art of the Deal” cover vaccines? Is patient privacy a relic of the past? And how big can biotech get in China?
Listen
Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back from 2020-02-27T22:04:20
Is the market overreacting to the coronavirus? Why do so many clinical trials go unfilled? And how do you pronounce "Martin Shkreli"?
Listen
Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review from 2020-02-20T21:35:56
Can biopharma police itself? Who decides whether something's a disease or a difference? And will fecal matter ever become a drug?
Listen
Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy from 2020-02-13T21:38:01
What's the right way to give drugs away? Is $3 billion even a lot of money? And when is biotech hype justified?
Listen
Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore from 2020-02-06T21:22:50
Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us a call?
We're coming up on the 100th episode of this podcast, and we're using the occasion to actualiz...
Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern from 2020-01-30T21:23:31
Is it wise to lie to the feds? Is pharma taking Sen. Bernie Sanders seriously? And what constitutes a "public health emergency of international concern?"
Listen
Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos from 2020-01-23T21:06:48
Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about?
Listen
Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap from 2020-01-16T21:33:04
Why weren't there any big deals announced this week? What does the word "equivalar" mean? And why is information about prognosis so hard to find?
Listen
Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga from 2020-01-09T19:49:37
Does pharma deserve more credit? Will history forgive He Jiankui? And how does a laboratory eureka become a lifesaving vaccine?
Listen
Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease from 2019-12-19T21:12:23
Which drug defined the decade? Who's the worst CEO in biopharma? And how does gene therapy actually work?
Listen
Episode 91: CAR-T's future, an alarming cancer trend & Chris Garabedian on Sarepta's FDA legacy from 2019-12-12T21:10:20
Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016?
Listen
Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep from 2019-12-05T22:31:53
How do you know if a "positive" study is positive? And how did one-eyed sheep lead to a drug for certain cancers?
Listen
Episode 89: Warren's awkward home front, a dwarfism drug, and the sound of STAT Summit from 2019-11-22T20:26:26
Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people taller? And when will AI come up with a new drug?
Listen
Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter from 2019-11-14T20:58:59
Do you trust Google with your health data? Is "Gattaca" an outdated reference? And what's it like to get dunked on?
Listen
Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday from 2019-11-07T20:56:38
Why hope for China's new Alzheimer's drug turned into skepticism ? Is three a crowd in CAR-T? And what's a Bionomy?
Listen
Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation' from 2019-10-31T21:12:18
When should a drug be pulled from shelves? How do you pronounce "HLTH?" And how does Ann Coulter decide what to tweet?
Listen
Episode 85: Every angle on Biogen's shocking Alzheimer's news from 2019-10-24T21:37:17
What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that...
Listen
Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from from 2019-10-17T20:39:23
Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog?
Listen
Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology from 2019-10-10T20:37:47
STAT's Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology indu...
Listen
Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood from 2019-10-03T20:17:19
Does impeachment have a pharma angle? Who's to blame for drug shortages? And why is Wall Street down on biotech?
Listen
Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing from 2019-09-26T20:45:03
What do we talk about when we talk about "vape"? Are there limits to business of DNA testing? And how hard is it to get yourself CRISPR'd?
STAT's Megan Thielking joins the gang to break do...
Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter from 2019-09-19T21:26:30
Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet?
Listen
Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure from 2019-09-12T18:39:07
House Speaker Nancy Pelosi’s drug pricing plan is aggressive, but is it viable? Can Moderna turn cells into tiny drug-making factories? What’s it like to cure your own rare disease?
Listen
Episode 78: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue from 2019-09-05T20:10:15
What separates good drug companies from mediocre ones? Have biohackers sold out? And who's going to run the FDA?
Listen
Episode 77: Purdue, J&J, and a week of big opioid crisis news from 2019-08-29T20:03:01
What does Dr. Richard Sackler sound like? When is $500 million a small amount of money? And what will come of the drug companies at the heart of the opioid crisis?
Listen
Episode 76: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech from 2019-08-22T21:02:14
How should you talk to friends about rejection? Can Facebook actually improve the lives of children? And how's biotech doing in China?
Listen
Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study from 2019-08-15T20:23:57
Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work?
Listen
Episode 74: Novartis and the no good, very bad week from 2019-08-08T20:35:25
Why did Novartis (NVS) keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?
Listen
Episode 73: Canadian pills, corporate jets, & racists with spit kits from 2019-08-01T20:36
Will Canada run out of drugs? Should you ever read your partner's diary? And what does Pepe the Frog know about genomics?
Listen
Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health from 2019-07-25T20:36:47
What makes an epidemic newsworthy? Can biotech succession succeed? And what's so novel about digital health?
Listen
Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety from 2019-07-18T19:16:06
Can apps treat anxiety? Is Gilead Sciences back on track? And are we all just brains in a vat?
Listen
Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech from 2019-07-11T20:32:15
Is drug pricing too complex for the Trump administration? Would you recognize Tom Hanks at a party? And what does it mean when famous executives quit?
Listen
Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing from 2019-06-27T20:50:46
Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?
Listen
Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life from 2019-06-20T20:29:22
Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all?
Listen
Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world from 2019-06-13T21:02:03
Is biohacking a crime? Who came up with the latest CRISPR trick? And did Rage Against the Machine sell out?
Listen
Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party from 2019-06-06T20:34:23
Who won ASCO? Is pharma sandbagging its blockbusters? And what do gladiators have to do with biotech?
Listen
Episode 65: A special episode from the halls of the ASCO meeting from 2019-06-04T20:34:39
What can be done to improve HPV vaccination rates in the U.S.? How does the genetic signature of a tumor lead to an effective cancer drug? What’s it like being a doctor and a cancer patient?
Listen
Episode 64: Feuding professors, failing businesses, and journalism 101 from 2019-05-30T20:00:50
Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?
Listen
Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer from 2019-05-23T21:20:16
What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?
Listen
Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials from 2019-05-16T20:35:34
Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?
Listen
Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA from 2019-05-09T20:12:57
Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?
Listen
Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms from 2019-05-02T21:14:47
Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?
Listen
Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup from 2019-04-25T20:24:02
Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?
Listen
Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print from 2019-04-18T20:05:15
Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?
Listen
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst from 2019-04-11T21:08:26
How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?
Listen
Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound from 2019-04-04T21:57:17
What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?
Listen
Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges from 2019-03-28T20:29:12
Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?
Listen
Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores from 2019-03-21T21:20:32
Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?
Listen
Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen from 2019-03-14T21:11:19
Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?
Listen
Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation from 2019-03-07T23:30:24
Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?
Listen
Episode 51: CEOs at the Senate, merger mania, and sleuthing startups from 2019-02-28T23:21:35
Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?
Listen
Episode 50: A big scoop on opioid marketing from 2019-02-22T18:29:22
What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?
Listen
Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill from 2019-02-21T22:14:47
Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT...
Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH from 2019-02-14T22:40:35
When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?
Listen
Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from? from 2019-02-07T23:31:10
Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?
Listen
Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns from 2019-01-31T21:56:52
Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?
Listen
Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics from 2019-01-24T22:37:23
Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?
Listen
Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics from 2019-01-17T22:05:10
Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?
Listen
Episode 43: A people's history of J.P. Morgan from 2019-01-10T23:30:30
Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?
Listen
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring from 2019-01-03T23:05:40
Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?
Listen
Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta from 2018-12-20T22:08:35
What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?
Listen
Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests from 2018-12-13T22:05:19
Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?
Listen
Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history from 2018-12-06T21:05:08
Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?
Listen
Episode 38: Your guide to the #CRISPRbabies controversy from 2018-11-29T21:26:23
What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?
Listen
Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts from 2018-11-15T22:15:11
Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?
Listen
Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug from 2018-11-08T22:31:03
Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?
Listen
Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence from 2018-11-01T22:05:14
Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?
Listen
Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma from 2018-10-25T21:14:41
Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?
Listen
Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy from 2018-10-18T21:07:35
Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?
Listen
Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn from 2018-10-11T20:13:40
Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?
Listen
Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round from 2018-10-04T17:50:26
Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?
Listen
Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics from 2018-09-27T20:38:47
Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?
Listen
Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem from 2018-09-20T20:32:37
Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?
Listen
Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping from 2018-09-13T21:46:59
Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?
Listen
Episode 27: Live from Boston! from 2018-09-06T21:31:06
Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.
Listen
Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer from 2018-08-30T19:10:10
Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?
Listen
Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags from 2018-08-23T19:07:41
Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?
Listen
Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T from 2018-08-16T20:27:54
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?
Listen
Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers from 2018-08-09T20:03:26
Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?
Listen
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest from 2018-08-02T20:55:44
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist...
Listen
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data from 2018-07-26T20:19:42
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
Listen
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season from 2018-07-19T22:56:17
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.
Listen
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines' from 2018-07-12T21:57:11
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
Listen
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts from 2018-07-05T21:14:23
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.
Listen
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China from 2018-06-28T22:03:26
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
Listen
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype from 2018-06-21T22:10:21
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?
Listen
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT from 2018-06-14T22:22:04
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?
Listen
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO from 2018-06-07T22:24:18
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.
Listen
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO? from 2018-05-31T21:38:06
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?
Listen
Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen from 2018-05-24T21:40:47
How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.
Listen
Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes from 2018-05-17T22:02:28
What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?
Listen
Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office? from 2018-05-10T21:58:18
On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer confer...
Listen
Episode #9 - Bill Gates on deadly flu, Chinese biotech bubbles, Golden State killer genetics from 2018-05-03T21:59:44
We talk to Bill Gates about the flu that could kill millions. Is China too enamored with biotech startups? And how do you find a cold case killer? Genetics.
Listen
Episode #8 - Megamergers, migraines, and biotech's Four Horsemen from 2018-04-26T21:11:47
What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?
Listen
Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism from 2018-04-19T22:45:52
Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?
Listen
Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR from 2018-04-12T21:17:43
Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?
Listen
Episode #5 - The FDA's cold shoulder, the latest CAR-T contender, and BuzzFeed's scoop on Grindr from 2018-04-05T21:10:35
What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?
Listen
Episode #4 - Mr. Drug CEO doesn't go to DC, billionaires fighting drug prices, a biotech report card from 2018-03-29T21:06:46
Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?
Listen
Episode #3 - A gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try? from 2018-03-22T21:03:04
What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?
Listen
Episode #2 - Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies from 2018-03-15T21:51:06
Did Elizabeth Holmes get off easy? Why does biotech bother with SXSW? And what does shoving a tube into a dead cow’s throat have to do with biotech?
Listen
Episode #1 - Shkreli's sentence, biotech froth, and a blood party from 2018-03-08T23:06:01
How long is Martin Shkreli going to be in prison? Is the biotech bubble about to burst? And what's it like to attend a blood-swapping gala? Listen to our first episode of, "The Readout LOUD."
Listen
Coming soon: "The Readout LOUD" from 2018-03-02T18:03:10
An introduction to a new weekly biotech podcast from STAT.
Listen